Deckers Outdoor Corp vs Medpace Holdings Inc — how do they compare? Deckers Outdoor Corp trades at $82.62 (market cap $10.95B), while Medpace Holdings Inc trades at $602 (market cap $16.87B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Deckers Outdoor Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Medpace Holdings Inc for 14 Days on average.
| DECK | MEDP | |
|---|---|---|
Market Cap | $10.95B | $16.87B |
Volume | 3,090,240 | 207,570 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $630.19 |
52-Week Low | $77.51 | $393.42 |
Typical Hold Time | 71 Days | 14 Days |
Enterprise Value | $9.82B | $16.48B |
Signals from Pluang's Aura AI — not financial advice
Deckers Outdoor (DECK) trades at $80.38, down 1.57% today, with strong fundamentals including 19.37% net margin and consistent earnings beats. The stock shows neutral technical signals with support at $78-79 and resistance at $81-82. Revenue growth has accelerated from $3.2B in 2022 to $5.0B in 2025, while profitability metrics remain robust with 42.56% ROE.
DECK presents a compelling value opportunity with attractive valuation multiples (P/E 11.43, EV/EBITDA 7.06) and 46% upside to consensus price target of $117.13. Risks include potential margin pressure from competitive footwear market and projected negative cash flow in 2026. Analyst sentiment leans bullish with 45% buy ratings versus 11% sell recommendations.
MEDP trades at $604.25, up 0.22% with neutral technical signals and strong fundamental performance. The stock shows robust profitability with 17.67% net income margin and consistent earnings beats in recent quarters. Recent news highlights institutional activity including CEO stock sales and upcoming Q3 2026 earnings report on October 21, 2026. Technical indicators show mixed signals with RSI neutral and ADX bullish, while support sits at $589 and resistance at $629.
MEDP presents a mixed outlook with strong fundamentals offset by high valuations and insider selling. The 21% buy rating from analysts suggests cautious optimism, with $620.44 price target offering 2.7% upside. Key risks include elevated P/E ratio of 35.5 and recent CEO stock sales totaling over $44 million in September 2026. Positive cash flow projection for 2026 supports growth potential despite current net outflow.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →